These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 38744633)

  • 21. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
    Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
    Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
    Maiorano BA; Catalano M; Maiello E; Roviello G
    Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.
    Taguchi S; Kawai T; Nakagawa T; Kume H
    Jpn J Clin Oncol; 2024 Mar; 54(3):254-264. PubMed ID: 38109484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
    Jain RK; Skelton WP; Zhang J
    Cancer Manag Res; 2020; 12():8379-8386. PubMed ID: 32982431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
    Moussa M; Papatsoris A; Abou Chakra M; Dellis A
    Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin.
    Choules MP; Zuo P; Otsuka Y; Garg A; Tang M; Bonate P
    J Pharmacokinet Pharmacodyn; 2023 Aug; ():. PubMed ID: 37632598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context.
    Hoffman-Censits J; Maldonado L
    Onco Targets Ther; 2022; 15():1519-1529. PubMed ID: 36545447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enfortumab vedotin - next game-changer in urothelial cancer.
    Maas M; Stühler V; Walz S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
    [No Abstract]   [Full Text] [Related]  

  • 35. How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma.
    Larroquette M; Lefort F; Domblides C; Héraudet L; Robert G; Ravaud A; Gross-Goupil M
    Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Klümper N; Eckstein M
    Eur Urol Focus; 2024 Apr; ():. PubMed ID: 38631991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfortumab Vedotin in urothelial cancer.
    Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
    Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.